Synapse - Works

Results (116624)

Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Meeting Abstract

de Wit, R.; Kulkarni, G. S.; Uchio, E.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

Meeting Abstract

Diaz, L. A.; Le, D.; Maio, M.; Ascierto, P. A.; Geva, R.; Motola-Kuba, D.; André, T.; Van Cutsem, E.; Gottfried, M.; Elez, E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Meeting Abstract

Banerjee, S.; Vergotte, I.; Colombo, N.; Barve, M.; Grisham, R.; Mehr, K. T.; Falk, M.; Beier, F.; Hennessy, M.; Schroeder, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs)

Meeting Abstract

Bauer, S.; Lewis, J. H.; Gelderblom, H.; van de Sande, M.; Stacchiotti, S.; Healey, J. H.; Tap, W. D.; Wagner, A. J.; Pousa, A. L.; Druta, M.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

Meeting Abstract

Bendell, J.; Lieu, C.; Raghav, K. P. S.; Argilés, G.; Cubillo, A.; Qu, X.; Yan, Y.; Merchant, M.; Zeuner, H.; Gallo, J. D.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results

Meeting Abstract

Borazanci, E.; Schram, A.; Brana, I.; Vieito Villar, M.; Garralda, E.; Spreafico, A.; Oliva, M.; Lakhani, N.; Wasserman, R.; Hoffman, K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

Meeting Abstract

Abou-Alfa, G. K.; Borbath, I.; Clarke, S. J.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D. Y.; Spratlin, J. L.; Valle, J. W.; Weiss, K. H.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Meeting Abstract

Albiges, L.; Rini, B. I.; Haanen, Jbag; Motzer, R. J.; Kollmannsberger, C. K.; Negrier, S.; Nole, F.; Bedke, J.; Bilen, M. A.; Nathan, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study

Meeting Abstract

Alsina, M.; Tabernero, J.; Arkenau, H. T.; Squadroni, M.; Doi, T.; Faustino, C.; Ghidini, M.; Mansoor, W.; Shitara, K.; Van Cutsem, E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Patient-reported outcomes from patients with Waldenstrom macroglobulinemia treated with ibrutinib-rituximab: Results from iNNOVATE study

Meeting Abstract

Matous, J. V.; Tedeschi, A.; Dimopoulos, M. A.; Trotman, J.; Garcia-Sanz, R.; Macdonald, D.; Mahe, B.; Herbaux, C.; Heffner, L.; Tam, C. S.; more...
American Journal of Hematology (2019)

Fulltext@MSK | Save